HENLIUS (02696) surged over 8% in afternoon trading, reaching a high of HK$85.95 to hit new record levels. As of press time, the stock was up 6.14% to HK$83.85 with a trading volume of HK$95.14 million.

On the news front, HENLIUS recently announced a strategic partnership with Qingde Pharmaceutical. Under the agreement, HENLIUS will acquire the development and exclusive commercialization rights for GQ1005, an innovative HER2-targeted antibody-drug conjugate (ADC) developed by Qingde, in China and specific overseas countries and regions. The drug is currently in Phase III clinical trials and is intended for the treatment of HER2-positive breast cancer.

According to public information, GQ1005 is an innovative HER2-targeted ADC drug developed by Qingde based on its proprietary enzymatic site-specific conjugation technology. Preclinical studies have shown that GQ1005 demonstrates anti-tumor activity comparable to trastuzumab deruxtecan across multiple tumor cell line xenograft models, with significant safety advantages.

Breast cancer represents a core therapeutic area that HENLIUS has strategically focused on. The company has established a diversified product pipeline covering the full disease course and all molecular subtypes of breast cancer. Through its self-built commercialization team and partnerships with overseas collaborators, HENLIUS has assembled a global commercialization network, continuously unlocking the commercial value of its breast cancer pipeline.